XML 31 R19.htm IDEA: XBRL DOCUMENT v3.25.3
Segment Information
 9 Months Ended
Sep. 30, 2025
Segment Reporting [Abstract]  
Segment Information Segment Information
The Company operates as one operating segment, the research and development of its investigational drug product. The Company used the management approach to determine its reportable operating segment. The Company's Chief Operating Decision Maker ("CODM") is its Chief Executive Officer, who reviews financial information presented on a consolidated basis. The Company is a clinical-stage pharmaceutical company and has limited revenue associated with a license and collaboration agreement. The CODM uses net loss as a measure of profit and loss, and assesses Company performance through the achievement of its clinical development goals. The CODM is regularly provided with budgeted and forecasted expense information which is used to determine the Company’s liquidity needs and cash allocation to its development programs. The CODM uses cash and marketable securities as a measure of segment assets in managing the enterprise.
The Company had revenue of $0 and $70 thousand for the three and nine months ended September 30, 2025, respectively, and $0 and $0 for the three and nine months ended September 30, 2024, respectively. Depreciation and amortization expense was $44 thousand and $131 thousand for the three and nine months ended September 30, 2025, respectively and $42 thousand and $133 thousand for the three and nine months ended September 30, 2024, respectively. Equity method investment expense was $0 and $0 for the three and nine months ended September 30, 2025, respectively, and $30 thousand and $130 thousand for the three and nine months ended September 30, 2024, respectively.
The following table illustrates our segment information for significant operating expenses and includes a reconciliation to net loss for the three and nine months ended September 30, 2025 and 2024:

 Three Months Ended September 30,Nine Months Ended September 30,
 2025202420252024
Revenue$— $— $70 $— 
Operating Expenses:
Research and development by significant expense:
  BOLSTER trial829 475 2,222 2,820 
  ASCEND trial8 133 61 271 
  Chemistry, manufacturing and controls157 764 543 1,703 
  Clinical department654 1,001 2,802 3,191 
  Other (1)
311 169 1,187 399 
Research and development1,959 2,542 6,815 8,384 
General and administrative by significant expense:
  Corporate1,068 1,183 3,370 3,587 
  Investor relations/public relations/communications306 338 946 969 
  Finance539 562 1,706 1,727 
  Legal183 174 734 1,084 
  Business development134 120 401 437 
  Share based compensation expense195 292 811 860 
  Other (2)
30 125 417 412 
General and administrative2,455 2,794 8,385 9,076 
Operating loss(4,414)(5,336)(15,130)(17,460)
Other income, net165 406 536 1,287 
Benefit from income taxes— — (962)(798)
Net loss$(4,249)$(4,930)$(13,632)$(15,375)
Cash, cash equivalents, and marketable securities$18,998 $35,856 
 (1) Included in Other are the GBM study,
     FORTIFIDE study and research oncology
     expenses
 (2) Included in Other are facilities expense, human
     resource and information technology expenses